NGF and Miyoshi myopathy: In the last few years, applying an NGF approach, based on processing at least 10 × 106 PB cells/tube stained with the two-tube/eight-color EuroFlow-IMF MM MRD antibody panel, the limit of detection can be set at 20 tumor plasma cell events, resulting in ~two-fold increased frequency of cases presenting with CTPC in PB by NGF vs. both immunocytochemistry and conventional flow cytometry, among MGUS, smoldering and active MM [23,24].